06. bab v - lampiran

5/26/2018 06. Bab v - Lampiran

1/34

BAB V

PENUTUP

A. Kesimpulan

Berdasarkan data yang dikumpulkan dan analisis serta pembahasan yang

dilakukan, maka dapat disimpulkan sebagai berikut:

1. Golongan antipsikotik yang paling besar digunakan pada tahun 2010

berdasarkan perhitungan DDD dalamATC adalah Risperidon dengan persen

penggunaan 47,20 dan Golongan antipsikotik yang paling besar digunakan

pada tahun 2011 berdasarkan perhitungan DDD dalam ATC adalah

Risperidon dengan persen penggunaan 51,5.

!ara pemberian yang dilakukan dengan oral dan parenteral.

Bentuk sediaan yang diberikan tablet dan in"eksi

2. #bat$obat yang masukDU 90% diurut berdasarkan besar penggunaan yaitu%

&ahun 2010 : Risperidon, &ri'luopera(in, )aloperidol.

&ahun 2011 : Risperidon, &ri'luopera(in, )aloperidol.

*. #bat yang digunakan di dalam penelitian ini sudah sesuai dengan

+ormularium Rumah akit tahun 2011.

B. Saran

1. Bagi Rumah akit -ia /aerah urakarta

epada pihak rumah sakit disarankan untuk meningkatkan pelayanan

medik terutama dalam pengobatan terhadap pasien ski(o'renia dengan tetap

52


2/34

5*

memantau e'ek samping obat antipsikotik yaitu sindrom parkinson, terutama

untuk obat$obat baru, pasien yang baru mendapat pengobatan serta pada pasien

yang akan menghentikan pengobatan.

2. Bagi peneliti selan"utnya

/iharapkan bagi peneliti selan"utnya untuk melakukan penelitian seara

analisa kualitati' pada penelitian penggunaan antipsikotik agar semakin

berkembangnya in'ormasi$in'ormasi yang menakup tentang antipsikotik.


3/34

DAFTAR PUSTAKA

Buku tandar elayanan 3edis edokteran -ia Reisi , 2010, tandarelayanan sikiatrik Rumah akit -ia /aerah urakarta, Gangguan

Mental Dan Priaku, struktur Klasifikasi Gangguan Jiwa Dan Prilaku

Birkett, /.-., 2002, The Future of ATCDDD an! Drug Utili"ation #esea$h. 6)#

/rug n'ormation ol.1 no.*.

British 3edial ssoiation, 2004, ritish &ational For'ular( )*, Royal

harmaeutial oiety o' Great Britain, Germany

!rismon, 3.8., /orson, .G., 2002, hi(ophrenia, /ipiro, -.&.,&albert, R.8., 3at

9he,G.R., ee,G.! and 6ells, 8.3.,Phar'a$othera+i ;athophysiologipproah$1241. 3 Gra$)ill,ne, ?e ork.

/epertemen kesesehatan. 200@. nfor'atoriu' -.at &asional n!onesia/ Badan

#3 R.

/epkes R, edoman engolongan dan /iagnosa Gangguan -ia edisi , tahun

1>>, Diagnosis Gangguan Jiwa halaman 4, enerbit /irektorat

esehatan -ia /irektorat -enderal elayanan 3edik, Rusdi 3aslim.

/epkes R 200>, # ndonesia Aolume 44. -akarta: katan ar"ana +armasi

ndonesia.

+atemi, .)., +olsom, &./., 200>, The &euro!eelo+'ental 1(+othesis of2$hi"o+hrenia, Reisited, hi(ophrenia Bulletin ol.*5no.*pp.52@

54@,200>,http:CCs h i( op h re ni a bull e tin.o D ' o r d"ou r n a ls.o r g C ont e ntC*5C*C52@.

' ull.pd ' ,diakses tanggal 1 -uni 2012.

+E, 2007,Far'akologi !an Tera+i edisi 5, -akarta : /epartemen edokteran

Eniersitas ndonesia.

+ormularium Rumah akit -ia /aerah urakarta halaman 15 =disi &ahun 2011.

mron R.2011, Gangguan Jiwa, httpCimron4html.blogspot, di akses tanggal 25?oember 2011

+, 200@, 2- Far'akotera+i, halaman 2@@$2@>, enerbit & + enerbitan

-akarta.

8aksman, &.). 200*,Ka'us Ke!okteran, enerbit /"ambatan

8indner, 8.3., 3arasiulo, .!., +arias, 3.R., Grohs, G.=.3., 200>,3$ono'i$

ealuation of anti+s($hoti$ !rugs for s$hi"o+hrenia treat'ent within the

ra"ilian 1ealth$are 2(ste', Re aFde Fblia.

54
http://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdf


4/34

55

#lson, -., 1>>*, Clini$al Phar'a$olog(4 Ma!e #i!i$ulousl( 2i'+le, &he

3Gra$)ill =duation.

ersson, .B., 200, The Anato'i$al Thera+euti$ Che'i$al ;&!< Classifi$ation

an! ts Use n The &or!i$ Coutries, /epartement o' ubli )ealth and

!aring ienes, Eppsala Eniersity, Eppsala, eden.

/=RH usat /ata dan n'ormasi $ erhimpunan Rumah akit eluruh

ndonesia, Pengo.atan 2ki"ofrenia Tak isa 500 Persen/ 200>.

http ://www.pdp ersi.o .id. kses pada tanggal 1> noember 2011.

hoenstadt, ., 200>, 36tra+(ra'i!al 2('+to's,.s hi ( oph re ni a .e m e dt. om,diakses tanggal 1 -uni 2012.

iregar,!. -. ., 200*,Far'asi #u'ah 2akit Teori !an Penera+an, enerbit Buku

edokteran =G!, -akarta, halaman >0$>1.

uhesti, &. 200>. 2ki"ofrenia Paranoi! !an Gangguan Delusional. +akultas

edokteran.Eniersitas &risakti -akarta

&"ay ). & I irana. R. 2002, -.at7-.at Penting. =leD 3edia omputindo

Gramedia, -akarta

&"ay ). &. I irana. R. 2007. -.at7-.at Penting. =disi A. /epartemen

esehatan R.

Aiedebek, heila 8., tahun 200@ Definisi Kesehatan Jiwa, 8andasan

eperaatan esehatan -ia, -akarta.

6.= 3aramis, 1>>4, l'u Ke!okteran Jiwa, halaman 215$2@>, enerbit ir

8angga Eniersity ress.

6)#, 200*, Drug an! Thera+euti$s Co''ittees A Pra$ti$al Gui!e, 6)#,

it(erland, halaman 71$@0.

6)#, 200, 81- Colla.orating Centre For Drug 2tatisti$ Metho!olog(,

?oregian nstitute o' ubli )ealth, #slo.

6)#, 2011, Gui!elines For ATC Classifi$ation an! DDD assign'ent 055,

6)# !ollaborating !entre +or /rug tatistis 3ethodology, #slo.
http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.schizophrenia.emedtv.com/http://www.schizophrenia.emedtv.com/http://www.schizophrenia.emedtv.com/http://www.pdpersi/http://www.schizophrenia.emedtv.com/


5/34

5

8ampiran 1. urat ermohonan engambilan /ata


6/34

57

8ampiran 2. urat eterangan enelitian


7/34

5@

8ampiran *.+ormularium R-/ urakarta &ahun 2011


8/34

5>

8ampiran 4. Rekapitulasi 8aporan elayanan Raat nap R-/ urakarta &ahun 2010 dan 2011

REKAPITULASI LAPORAN PELAYANAN RAWAT INAP RSJD SURAKARTA TAUN !"#"?o -enis egiatan -an +eb 3ar pr 3ei -un -ul gust ep #kt ?op /es &otal

1 asien masuk 1>@ 202 252 221 1>5 2*1 1>0 21 222 21@ 224 1>@ 257

2 asien keluar 20@ 1>4 214 240 22@ 21 207 22* 214 211 21@ 1> 25>

J hidupJ mati K 4@ "am 1 1

J mati L 4@ "am 1 1 2

* )ari peraatan 54>7 4*> 521 252 5**@ 5524 5*4* 520 45>5 54>0 51@@ 522> *>22

4 8ama raat 145 424 5540 5@>> 501 50@@ 44* 5@*@ 4@*2 44@ 5157 47@ *01

8# 2>hr 24hr 25hr 24hr 2@hr 21hr 22hr 2hr 22hr 21hr 22hr 24hr 2@@hr

8# &ahun 2010 25 hari

REKAPITULASI LAPORAN PELAYANAN RAWAT INAP RSJD SURAKARTA TAUN !"##?o -enis egiatan -an +eb 3ar pr 3ei -un -ul gust ep #kt ?op /es &otal

1 asien masuk 1@ 1@@ 1@@ 1>5 201 245 242 240 2@5 214 207 21@ 20>

2 asien keluar 202 10 227 1@1 1>2 202 221 2** 242 25 217 201 254*

J hidup

J mati K 4@ "am

J mati L 4@ "am 1 1* )ari peraatan 54*0 4727 52>* 51*4 57>5 *@2 7*17 7477 7@40 7542 *>1 7200 752@

4 8ama raat 22@ *75@ 5>04 4*>0 5207 504 747 >4 7>* 7@* 5> *2* 7*007

8# *0hr 1@hr 25hr 24hr 2hr 27hr 2>hr 2@hr *1hr 2@hr *0hr *1hr *27hr

8# &ahun 2011 27 hari

5>


9/34

0

0

8ampiran 5. /ata ntipsikotik asien Raat nap R-/ urakarta &ahun 2010 dan 2011 ;hi(o''enia< +20

DATA ANTIPSIKOTIK PASIEN RAWAT INAP RSJD SURAKARTA TAUN !"#" $S%&i'())enia* F!"

N( Nama (+a, Jan Fe+ -ar Apr -ei Jun Jul Aus, Sep O/, N(p Des T(,al

1 )aloperidol C odomer 5 mg 7*@ 104@ 11** 41@ *27 4* 524 22 174 140 170 545

2 )aloperidol C Gootil 5 mg *51 47 424 *50 07 472 2*0 27 150 *2@ 270 14>@ 5417

* )aloperidol C )aldol 2 mg 10 14 2>4 Risperidone C Risperdal 2 mg 10 147 2 40 @ 45 >0 15 20 22 25 51 70>

5 Risperidone C ?oprenia 2 mg 1551 15@2 2*@4 21@ 172 @77 1505 1@4> 1@24 20*2 17 >@ 2014@

Risperidone C ersidal 2 mg 144 1>1 1212 225* *>1 2041 1*5 141> 142 10 1270 1@>4 121

7 Risperidone C 9o'redal 2 mg 2@>2 2220 27@2 204* *217 247* 2701 24>4 252 2*> 2447 1412 2>57

@ &ri'luopera(in C tela(in 5 mg 4** *** 507 457> *@41 5>11 514 40> 45*2 500> 550> 4744 452

> !hlorproma(ine 100 mg 147 177 255 1>1@ 1@14 12 15 11 10> 170* 15@ 14@7 20@41

10 lo(apin C !lo(aril 100 mg 17 *> 70 7* 5 200 27> @4 14 5 1 *4 12*@

11 lo(apin C !lo(aril 25 mg 114* 4 @* >00 744 125 41@ 50@ 45> 575 755 107 7>50

12 lo(apin C 8u'ten 100 mg 15 *0 *0 *0 *0 15

1* lo(apin C 8u'ten 25 mg 10 70 *0 *0 1>5 15@ 15 0 1>5 100 10 @7*

14 lo(apin C !lorieD 100 mg 457 2 * 15 5> 24 *5 1>

15 lo(apin C !lorieD 25 mg 7 0 7@ 24 21@ @* *5* 1>4 25 R 11>5

1 lo(apin C i(oril 25 mg 50 20 @0 150

17 3aprotiline C 25 mg 2>5 **0 *1@ 10 24 *11 2@5 54> *42 455 45 2*1 40051@ Muetrapine C eraNuel *00 mg 5* 24 1*> 2> 1 @0 7@ 107 @ 1*> 144 100 1040

1> 9otepin C 8odopin 50 mg 11* 240 1>2 4>@ *1@ 2>1 477 5@1 2* 275 41 25 *7>

20 ripipra(ole 10 mg *0 *> 107 *1 *2 2*>

n"eksi

1 !epe(et n"e

2 )aloperidol deanoat ampul 7 > 4 7 @ 4 > @ @ 14 @>


10/34

1

1


* )aloperidol C serenae 5 mgCml 52 52 *5 1*7 * 100 50 5 51 *> 5> 75 77@

4 #la(apine C 9ypreDa 10 mgCml 10 1 1 4 10 40 1 7

5 )aloperidol C lodomer 5 mgCml 111 1>0 10> 117 107 11* 7* 10 10@ 1 157 1 14**

DATA RAWAT INAP ANTIPSIKOTIK PASIEN RAWAT INAP RSJD SURAKARTA TAUN !"## $S%&i'())enia* F!"


1 )aloperidol C odomer 5 mg 54 21 24* 54 17 22@ 12 10 5@ >0 75 45 112

2 )aloperidol C Gootil 5 mg 174 214 2 442 1@11 24> 4>> 154 1@1> 1245 47 >5* 107*

* )aloperidol C )aldol 2 mg 77 *42 >1 1>4 5 174 2@ 44* 1>@ @0 2>5 541 2777

4 Risperidone C Risperdal 2 mg *4@ >>4 @1* 5*20 *27 *** 4@72 4@5> 420@ 0* 0>2 20* 5@@10

5 Risperidone C ?oprenia 2 mg 204 1@0 41 0 2>7 2* 47 4@1 *@ 1*1 57 20 *402

Risperidone C ersidal 2 mg 252 2*5 205 110 175 *@ 21@ 277 *22 7* 101 10@ 2444

7 Risperidone C 9o'redal 2 mg >@7 542 *74 *10 *11 452 **2 2>@ 541 17* 1@ 27* 471

@ &ri'luopera(in C tela(in 5 mg *2 4@71 47@ 474 515> 5172 444 2@5 >@> *@> 52@ 402 *575>

> !hlorproma(ine 100 mg 1775 15@4 25>4 10>5 *70 @4 1042 1* 121 11@1 1*0 1@* 1>*4>

10 lo(apin C !lo(aril 100 mg 4 4* 1* 25 * 5 4> 51 25 1@4 *74 @0

11 lo(apin C !lo(aril 25 mg 44 17 242 1> *2@ 2@* 245 **> 450 12 22 70 2>50

12 lo(apin C 8u'ten 100 mg 14 * 501* lo(apin C !lorieD 100 mg 5 @ 2@ 1@ 10 10 100 17>

14 lo(apin C !lorieD 25 mg 112 15@ 42 4> @4 451

15 lo(apin C i(oril 25 mg

1 3aprotiline C 25 mg 27 24 10 5 7 > 5 20 5* 5 15

17 Muetrapine C eraNuel *00 mg 147 >* > 4 21@ 17* 271 @ * *7 @0 @ 1**

1@ 9otepin C 8odopin 50 mg 44 @0 50 *@ > 20 114 15> 51 40 >2


11/34

2

2


n"eksi

1 )aloperidol deanoat ampul 2 1 5 1 5 14

2 )aloperidol C serenae 5 mgCml *> 11 5 14 > 1 @ 1 * 15 111

4 )aloperidol C lodomer 5 mgCml 227 72 >0 215 2>0 *07 70 1>5 4>* 255 *** 2* **@*


12/34

*

*

8ampiran . /ata enggunaan ntipsikotik asien Raat nap &ahun 2010 dan 2011

DATA PEN00UNAAN ANTIPSIKOTIK PASIEN RAWAT INAP TAUN !"#"

?o Golongan ode &! ?ama obat Bentuk

sediaan /osis terapi-umlah

pemakaian

uantitaspenggunaan

///;mg 0,11

?#5)04 Muetiapine tab 4hari 1:50 mg,100

mg,200 mg,*00 mg1040 *12000 400 7@0 45,*7 1,*7

4 #ther antipsyhotis

henothia(ines ith5 pipera(ine struture

?#5P0@ Risperidone tab 4$1@ mg 7254 1*450@ 5 2>01, 154,>5 47,2

?#5P11 9oteppine tab 75 mg$ *00 mg *74 1@*700 200 >1@,5 5*,4* 1,7

?#5P12 ripipra(ole tab 10$*0 mg 2*> 2*>0 15 15>,** >,2 0,2@

?#5B0 &ri'luopera(ine tab 2$20 mg 4521 22@105 20 11405,25 0*,4@ 20,01

**15,0


13/34

4

4

DATA PEN00UNAAN ANTIPSIKOTIK PASIEN RAWAT INAP TAUN !"##

?o Golonganode

&!?ama obat

Bentuk

sediaan/osis terapi

-umlah

pemakaian

uantitas

penggunaan

///

;mg5,5 @ @24@ 15,*4

*

/ia(epines, oDapines,thia(epines, andoDepines

?#5)02 !lo(apine tab maD 00 mg 44>0 *55025 *00 1,1@*.41 2,21

?#5)0* #lan(apine in" 10 mgChr

?#5)04 Muetiapine tab 4hari 1:50 mg,100

mg,200 mg,*00 mg

1** 400@00 400 1002 57,*5

15@>

>,02

1,@7

4 #ther antipsyhotis ?#5P0@ Risperidone tab 4$1@ mg >417 1*@@*4 5 27,7 51,5

?#5P11 9oteppine tab 75$*00 mg >2 *400 200 17* 0,*0

?#5P12 ripipra(ole tab 10$*0 mg

5

henothia(ines ith

pipera(ine struture

?#5B0 &ri'luopera(ine tab 2$20 mg *575> 17@7>5 20 @>*>.75 511,72 1,*

*07,12


14/34

5

8ampiran 7. &abel /E >0O &ahun 2010 dan 2011

Ta+el DU 1"2 Ta&un !"#"

?o ode &! ?amaO

penggunaankumulasi

egmen

/E

1 ?#5P0@ Risperidone 47,2 47,2

>0O2 ?#5B0 &ri'luopera(in 20,01 7,21

* ?#5/01 )aloperidol 14,4 @1,7

4 ?#501 !hlorproma(in 12,2 >*,@7

10O

5 ?#5)02 !lo(apin 2,75 >,2

?#5P11 9otepin 1,7 >@,24

7 ?#5)04 Muetiapin 1,*7 >>,1

@ ?#5P12 rippra(ole 0,2@ >>,@>

> ?#5)0* #lan(apin 0,11 100

Ta+el DU 1"2 Ta&un !"##

?o ode &! ?amaO

penggunaankumulasi

egmen

/E

1 ?#5P0@ Risperidone 51,5 51,5

>0O2 ?#5B0 &ri'luopera(in 1,* @,2@

* ?#5/01 )aloperidol 15,*4 @*,2

4 ?#501 !hlorproma(in 12,00 >5,2

10O5 ?#5)02 !lo(apin 2,21 >7,@*

?#5)04 Muetiapin 1,@7 >>,70

7 ?#5P11 9otepin 0,*0 100

5


15/34

8ampiran @. &!C/// berdasarkan 6)# Colla.orating Centre tahun 2011

0(l(nan K(3eATC Nama O+a, DDD Ben,u/Se3iaan

P h e no th ia z in e s w ith ?05B01 /i D y r a ( ine 50 mg #

pip e razi n e str u c tu re *0 mg

?05B02 + luph e n a ( ine 10 mg #

1 mg

?05B0* er ph e n a ( ine *0 mg #

7 mg

10 mg

1 mg R

?05B04 r o hlo r p era ( ine 0.1 g R

50 mg

0.1 g #

?05B05 &hiop r op a ( a te 0 mg #

?05B0 & r i' luop era ( ine 20 mg #

@ mg

20 mg R

?05B07 e toph en a ( ine 50 mg #

?05B0@ &hiop r op era ( ine 75 mg #

20 mg

?05B0> B ut a p e ra ( ine 10 mg #

?05B10 era ( ine 0.1 g #0.1 g

P h e no th ia z in e s w ith ?0501 ! hlo r p r om a ( ine 0.* g #

aliphatic sid e-c h a i n 0.1 g

0.* g R

?0502 8 e o m e p r om a ( ine 0.* g #

0.1 g

?050* r om a ( ine 0.1 g

0.* g #

?0504 ep r o m a ( ine 0.1 g #

50 mg

?0505 & r i' lup r om a ( ine 0.1 g #

?050 ! y a m e m a ( ine

0.1 g

?0507 ! hlo r p r o e th a ( ine

P h e no th ia z in e s w ith ?05!01 er i ia ( ine 50 mg #

pip e ridi n e str u c tu re 20 mg

?05!02 &hio r id a ( ine 0.* g #

?05!0* 3 e so r id a ( ine 0.2 g #

0.2 g

?05!04 ipoti a ( ine 10 mg #

5 mg
http://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC04&showdescription=yes


16/34

7

0(l(nan K(3eATC Nama O+a, DDDBen,u/

Se3iaan

Bu ty r op he no ne ?05/01 ) a lop er idol @ mg #d eri va t ives @ mg

*.* mg ?05/02 & r i' lup er idol 2 mg #

?05/0* 3 e lp er one 0.* g #

0.* g

?05/04 3op er one 20 mg

20 mg #

?05/05 ip a mp er one 0.2 g #

?05/0 B r omp er idol 10 mg #

10 mg

*.* mg

?05/07 B e np e r idol 1.5 mg #

?05/0@ / r op er idol

?05/0> + lu a nisone

I n do l e d eri va t ives ?05=01 # D y p er tine 0.12 g #?05=02 3olindone 50 mg #

?05=0* er tindole 1 mg #

?05=04 9 ip r a sidone @0 mg #

40 mg

T h ioxa n th e ne?05+01 + lup e nti D ol mg #

4 mg

?05+02 ! lop e nth iD ol 0.1 g #

0.1 g

?05+0* ! hlo r p r othi D e ne 50 mg

0.* g #

?05+04 &iot iD e ne *0 mg #

?05+05 9 u lo p e nthi D ol *0 mg #

15 mg

*0 mg

Diph e n

y lbut

y lpip e ri ?05G01 + luspi r il e ne 0.7 mg

d in e d eri va t ives ?05G02 imo ( ide 4 mg #?05G0* e n ' lu r idol mg #

Diazepines, ?05)01 8 o D a pine 0.1 g #oxazepines,

thiazepines and

?05)02 ! lo ( a pine 0.* g #

oxepines

?05)0* #l a n ( a pine

0.*

10

10

g

mg

mg

?05)04 Mu e ti a pine

10

0.4

mg

g

#

#

?05)05 s e n a pine 20 mg #

?05)0 ! loti a pine @0 mg #
http://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AEhttp://www.whocc.no/atc_ddd_index/?code=N05AE01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AFhttp://www.whocc.no/atc_ddd_index/?code=N05AF01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AG03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AEhttp://www.whocc.no/atc_ddd_index/?code=N05AE01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AFhttp://www.whocc.no/atc_ddd_index/?code=N05AFhttp://www.whocc.no/atc_ddd_index/?code=N05AF01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AG03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH06&showdescription=yes


17/34

@

0(l(nan K(3eATC Nama O+a, DDDBen,u/

Se3iaan

@0 mg B e n z a m id es ?05801 ulpi r ide 0.@ g #

0.@ g

?05802 ultop r ide 1.2 g #

?0580* &i a p r ide 0.4 g #0.4 g

?05804 R e mo D ip r ide 0.* g

0.* g #

?05805 misulp r ide 0.4 g #

?0580 A era lip r ide

?05807 8 e osulpi r ide 0.4 g #

it h iu m ?05?01 8 ithium 24 mmol #

!t h e r antips

yc h oti c s ?05P07 r othip e n d y l 0.24 g #0.24 g

?05P0@ R isp er idone 5 mg #

2.7 mg

?05P10 3os a p ra mine

?05P11 9 ot e pine 0.2 g #

?05P12 r ipip ra ( ole 15 mg #

15 mg

?05P1* a lip er idone mg #

2.5 mg ?05P14 lop e r idone
http://www.whocc.no/atc_ddd_index/?code=N05ALhttp://www.whocc.no/atc_ddd_index/?code=N05AL01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ANhttp://www.whocc.no/atc_ddd_index/?code=N05AN01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AXhttp://www.whocc.no/atc_ddd_index/?code=N05AXhttp://www.whocc.no/atc_ddd_index/?code=N05AX07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX11&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX12&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX13&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX14&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ALhttp://www.whocc.no/atc_ddd_index/?code=N05AL01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ANhttp://www.whocc.no/atc_ddd_index/?code=N05AN01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AXhttp://www.whocc.no/atc_ddd_index/?code=N05AX07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX11&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX12&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX13&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX14&showdescription=yes


18/34

>

Lampiran 9. Cara perhitungan obat

Tahun

2010

A. Risperidone

1. Jumlah hari rawat =1719

= Jumlah pasien masuk rawat inap Q LOS

= 1719 Q 19 !

= "#$%%

#. &osis 'ang digunakan di !umah Sakit

!isperidone/!isperdal # mg

= # mg

= 7(9 Q # = 1)1*

!isperidone/+oprenia #

mg !isperidone/,ersidal

# mg

= #(1)* Q #

= 1%*#1 Q #

= #97% Q #

= )(#9%

= ""%)#

= 91#

!isperidone total penggunaan Q = 1").(*

". 0uantitas penggunaan !isperidone = umlah obat Q kekuatan

= 1").(* mg

). &&& untuk !isperidone oral = mg

. &&& real =

kuantitas

penggunaan

&&&

1").(*=

= #%9(1.%

%. &&& / 1(( hr =&&&real

1719

Q 1((

= 1.%)$9


19/34

70

&&&/1((hr

Q7. ,ersen =

1((

1.%)$9=

""1$(%Q 1((

= )7.#(

B. Haloperidol

1. Jumlah hari rawat = 1719


= 1719 Q 19 !

= "#$%%

#. aloperidol/Lodomer mg = )% Q = #7"#

aloperidol/2o3otil mg = )17 Q = #7(*

aloperidol/aldol # mg = #) Q # = )*

aloperidol/&e4anoat mg = *) Q = )#(

aloperidol/Serena4e mg/ml = 77* Q = "*9(

aloperidol/Lodomer mg/ml = 1)"" Q = 71%

aloperidol total penggunaan Q kekuatan = %.9""mg

". 0uantitas penggunaan aloperidol = umlah obat Q kekuatan

= %.9"" mg

). &&& untuk aloperidol = * mg

. &&& real =kuantitas

penggunaan

&&&

%.9""=

*= *#)1$%"

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

*#)1$%"=

1719Q 1((

= )79$))


20/34

71

&&&/1((hr

Q7. ,ersen =

1((

)79$))

""1$(Q 1((=

=

C. CPZ

1. Jumlah hari rawat = 17$19

= Jumlah pasien masuk rawat inap Q LOS= 1719 Q 19 !

= "#$%%

#. &osis 'ang digunakan di !umah Sakit = 1(( mg

C,- 1(( mg total penggunaan = #(.*)1

C,- total penggunaan Q kekuatan = #(.*)1 Q 1((

= #.(*).1((

". 0uantitas penggunaan C,- = umlah obat Q kekuatan

= #.(*).1(( mg

). &&& untuk C,- oral = "(( mg


penggunaan

&&&

#.(*).1((

= "((= %.9)

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

%.9)=17$19

Q 1((

= )()$1"


21/34

72

&&&/1((hr

Q7. ,ersen =

1((

)()$1"

""1$(Q 1((=

=

D. TFP



= "#$%%

#. 56, total penggunaan = ).%#1

&osis 'ang digunakan di !umah Sakit = mg

56,/Stelain mg total penggunaan Q kekuatan = ).%#1 Q

= ##*.1(

". 0uantitas penggunaan 56, = umlah obat Q kekuatan

= ##*.1( mg

). &&& untuk 56, = #( mg


penggunaan

&&&

##*.1(=

#(= 11)($#

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

11)($#=

1719Q 1((

= %("$)*


22/34

7*

7. ,ersen penggunaan =&&&/1((hr

Qml &&&/1((hr selama 1

th

1((

%("$)*=""1$(%

Q 1((

E. Klozapin

1. Jumlah hari rawat =

1719

= #($(1


= 1719 Q 19 !

= "#$%%

0loapin total penggunaan = 119(

0loapin/Cloaril 1(( mg = 1#"* Q 1(( =1#"*((

0loapin/Cloaril # mg = 7)( Q # = 1*%#(

0loapin/Luten 1(( mg = )# Q 1(( = )#((

0loapin/Luten # mg = *7" Q # = #1*#

0loapin/Clorie8 1(( mg = %19 Q 1(( = %19((

0loapin/Clorie8 # mg = 119 Q # = #9*7

0loapin/Sioril # mg = 1( Q # = "7(

0loapin total penggunaan Q kekuatan = )%9.9((

#. 0uantitas penggunaan 0loapin = umlah obat Q kekuatan

= )%9.9(( mg

". &&& untuk 0loapin = "(( mg

). &&& real =kuantitas

penggunaan

&&&

)%9.9((=

"((


23/34

= 1%%$""

&&& real

. &&& / 1(( hr =ml hr rawatQ 1((

1%%$"""=

1719Q 1((

= 91$11

%. ,ersen penggunaan =&&&/1((hr

Qml &&&/1((hr selama 1 th

1((

91$11=""1$(%

Q 1((

F. Zotepin


1719

= #$7


= 1719 Q 19 != "#$%%

-otepin total penggunaan = ".%7)

&osis 'ang digunakan di !umah Sakit = ( mg

-otepin/Lodopin ( mg = "%7)

-otepin total penggunaan Q kekuatan = ".%7) Q ( mg

= 1*".7(( mg

#. 0uantitas penggunaan -otepin = umlah obat Q kekuatan

= 1*".7(( mg

". &&& untuk -otepin = #((

mg


penggunaan

&&&

1*".7((=

#((= 91*$


24/34

. &&& / 1(( hr =&&&real

ml hr rawat

Q 1((

91*$=

1719Q 1((

= "$)"



1((

"$)"=""1$(%

Q 1((

. !uetiapin


1719

= 1$%7


= 1719Q 19 != "#$%%

uetiapin/Serouel "(( mg total penggunaan= 1.()(

&osis 'ang digunakan di !umah Sakit = "(( mg

uetiapin total penggunaan Q dosis = 1.()( Q "(( mg

= "1#.(((

#. 0uantitas penggunaan uetiapin = umlah obat Q kekuatan

= "1#.((( mg

". &&& untuk uetiapin = )(( mg


penggunaan

&&&

"1#.(((=

)((

= 7*(&&& real

. &&& / 1(( hr =ml hr rawat

Q 1((


25/34

7*(=

1719Q 1((

= )$"7



1((

)$"7=""1$(%

Q 1((

H. Aripiprazole


1719

= 1$"7


= 1719 Q 19 !

= "#$%%

#. ;ripipraole 1( mg total penggunaan = #"9

&osis 'ang digunakan di !umah Sakit = 1( mg

;ripipraole total penggunaan Q kekuatan = #"9 Q 1( mg

= #."9(

". 0uantitas penggunaan ;ripipraole = umlah obat Q kekuatan

= #."9( mg

). &&& untuk ;ripipraole = 1 mg

. &&& real =

kuantitas

penggunaan&&&

#."9(=

1= 19$""

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

19$""

= 1719 Q 1((

= 9$#%


26/34

77

&&&/1((hr

Q7. ,ersen =

1((

9$#%

""1$(Q 1((=

=

". #lanzapine



= "#$%%

#. Olanapine/-'pre8a 1(mg/ml total penggunaan = %7

&osis 'ang digunakan di !umah Sakit = 1( mg

Olanapine total penggunaan Q kekuatan = %7 Q 1( mg

= %7( mg

". 0uantitas penggunaan Olanapine = umlah obat Q kekuatan

= %7( mg

). &&& untuk Olanapine = 1( mg


penggunaan

&&&

%7(=

1(= %7

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

%7=

1719Q 1((

= "$*9


27/34

7@

&&&/1((hr

Q7. ,ersen =

1((

"$*9

""1$(Q 1((=

=

TAH$%

2011

A. Risperidone

1. Jumlah hari rawat = 17)7


= 17)7 Q #) !

= )1$9#

#. !isperidone total penggunaan = %9.)17

&osis 'ang digunakan di !umah Sakit = # mg

!isperidone/!isperdal # mg = **1( Q # = 117%#(

!isperidone/+oprenia # mg =")(# Q # = %*()

!isperidone/,ersidal #mg =#))) Q # = )***

!isperidone /-oredal #mg = )7%1 Q # = 9##


28/34

7>

!isperidone total penggunaan Q kekuatan = 1"*.*") mg

". 0uantitas penggunaan !isperidone = umlah obat Q kekuatan

= 1"*.*") mg

). &&& untuk !isperidone oral = mg


penggunaan

&&&

1"*.*")=

= #7.7%

%. &&& / 1(( hr =&&&real

17)7

Q 1((

= 1.*9

7. ,ersen penggunaan = &&&/1((hr Qml &&&/1((hr selama 1

th

1((

1$*9="(7%$1#

Q 1((

= 1$%

B. Haloperidol



= 17)7 Q #) !

= )1$9#

#. aloperidol/Lodomer mg =11%# Q = *1(

aloperidol/2o3otil mg = 1(%7" Q =

aloperidol/aldol # mg = #777 Q # = )

aloperidol/&e4anoat amp (mg/ml

aloperido/Serena4e (mg/ml

= 1) Q (

= 111 Q

=7((

=


29/34

aloperidol total penggunaan Q kekuatan = %.9*)

". 0uantitas penggunaan aloperidol = umlah obat Q kekuatan

= %.9*) mg

). &&& untuk aloperidol oral = * mg


penggunaan

&&&

%.9*)=

*= *#)*

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

*#)*=

17)7Q 1((

= )7#$1#



1((

)7#$1#="(7%$1#

Q 1((

C. CPZ


17)7

= 1$")


= 17)7 Q #) !

= )1$9#

#. C,- total penggunaan = 19")9

&osis 'ang digunakan di !umah Sakit = 1(( mg

C,-1(( mg total penggunaan Q kekuatan= 19")9 Q 1((

= 19").9((

". 0uantitas penggunaan C,- = umlah obat Q kekuatan


30/34

= 1.9").9(( mg

). &&& untuk C,- oral = "(( mg


penggunaan

&&&

1.93).9((=

"((= %.))9.%%%

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

%.))9.%%%=

17)7Q 1((

= "%9$1*


Qml &&&/1((hr selama 1

th

1((

"%9$1*="(7%$1#

Q 1((

= 1#$((

D. TFP



= 17)7 Q #) !

= )1$9#

#. 56, total penggunaan = ".79

&osis 'ang digunakan di !umah Sakit = mg

56, mg total penggunaan Q kekuatan = ".79 Q

= 17*.79

". 0uantitas penggunaan 56, = umlah obat Q kekuatan


31/34

@2

= 17*.79

0loapin/Cloaril 1(( mg

0loapin/Cloaril # mg

= *%( Q 1(( = *%(((

= #9( Q # = 7"7(

0loapin/Luten 1(( mg = ( Q 1(( = (((

0loapin/Clorie8 1(( mg = 179 Q 1(( = 179((

0loapin/Clorie8 # mg

0loapin total penggunaan Q kekuatan

= )1 Q # = 11#7

=

". 0uantitas penggunaan 0loapin = umlah obat Q kekuat

). &&& untuk 56, = #( mg


penggunaan

&&&

17*.79=

#(= *9"9.7

%. &&& / 1(( hr = &&&real

ml hr rawat

Q 1((

*9"9$7=

1)7)7Q 1((

= 11$7#


Q

ml &&&/1((hr selama 1th

1((

511 ,72="(7%$1#

Q 1((

E. Klozapin


17)7

= 1%$%"


= 17)7 Q #) !

= )1$9#

#. 0loapin total penggunaan = ))9(

an


32/34

@*

= "(# mg

). &&& untuk 0loapin = "(( mg


penggunaan

&&&

"(#=

"((= 11*"$)1

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

11*"$)1=

17)7Q 1((

= %7$7"



1((

%7$7"

="(7%$1# Q 1((

F. Zotepin


17)7

= #$#1

0,!< = Jumlah pasien masuk rawat inapQ LOS

= 17)7 Q #) !

= )1$9#

#. -otepin total penggunaan = %9#

&osis 'ang digunakan di !umah Sakit = ( mg

-otepin ( mg total penggunaan Q kekuatan = %9# Q ( mg

= ")%(( mg

". 0uantitas penggunaan -otepin = umlah obat Q kekuatan

= ")%(( mg


33/34

). &&& untuk -otepin = #(( mg

. &&& real = kuantitaspenggunaan

&&&

")%((=

#((= 17"

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

17"=

17)7Q 1((

= 9$(#



1((

9$(#="(7%$1#

Q 1((

. !uetiapin


17)7

= ($"(

0,!< = Jumlah pasien masuk rawat inap Q LOS

= 17)7 Q #) !

= )1$9#

#. uetiapin "(( mg total penggunaan = 1.""%

&osis 'ang digunakan di !umah Sakit = "(( mg

uetiapin total penggunaan Q kekuatan = 1.""% Q "(( mg

= )((.*((

". 0uantitas penggunaan uetiapin = umlah obat Q kekuatan

= )((.*(( mg

). &&& untuk uetiapin = )(( mg


34/34


penggunaan

&&&

)((.*((=

)((= 1((#

&&& real%. &&& / 1(( hr =

ml hr rawatQ 1((

1((#=

17)7

Q 1((

= 7$"



1((

7$"="(7%$1#

Q 1((

= 1$*7

06. bab v - lampiran

Documents